Treatment of cutaneous and mucosal telangiectases in hereditary hemorrhagic telangiectasia: Report of three cases

Journal of Cosmetic and Laser Therapy

Volumn 9, Issue 1, 2007, Pages 29-33

  Fernández Jorge, Beatriz ^a,b   Losada, Jesús Del Pozo ^a   Paradela, Sabela ^a   Martínez González, Covadonga ^a   Fonseca, Edvardo ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

^b Hospital Abente y Lago   (Spain)

Author keywords

Hereditary hemorrhagic telangiectasia; Intense pulsed light; IPL; Laser; Mucocutaneous telangiectases; Rendu Osler Weber disease

Indexed keywords

ADULT; ANESTHESIA; ARTICLE; BLEEDING; CASE REPORT; CHEEK; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; LIP; NEODYMIUM LASER; OUTPATIENT; PRIORITY JOURNAL; PURPURA; RENDU OSLER WEBER DISEASE; SKIN DEFECT; TREATMENT OUTCOME;

ADULT; FEMALE; HUMANS; LASER THERAPY, LOW-LEVEL; MIDDLE AGED; PHOTOTHERAPY; TELANGIECTASIA, HEREDITARY HEMORRHAGIC;

EID: 34147215933     PISSN: 14764172     EISSN: 14764180     Source Type: Journal    
DOI: 10.1080/14764170601091687     Document Type: Article

References (62)

1. Swanson DL, Dahl MV. Embolic abscesses in hereditary hemorrhagic telangiectasia. J Am Acad Dermatol. 1991;24:580-3.
2. Folz BJ, Lippert BM, Wollstein AC, Tennie J, Happle R, Werner JA. Mucocutaneous telangiectases of the head and neck in individuals with hereditary hemorrhagic telangiectasia. Analysis of distribution and symptoms. Eur J Dermatol. 2004;14:407-11.
3. Begbie ME, Wallace GM, Shovlin CL. Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): A view from the 21st century. Postgrad Med J. 2003;79:18-24.
4. Morales Angulo C, Megia Lopez R, del Valle Zapico A, Mazon Gutierrez A, Garcia Mantilla J, Rama Quintela JJ. Rendu-Osler-Weber disease (hereditary hemorrhagic telangiectasia). Report of 30 cases. Acta Otorrinolaringol Esp. 1997;48:625-9.
5. Gallitelli M, Pasculli G, Fiore T, Carella A, Sabba C. Emergencies in hereditary haemorrhagic telangiectasia. Q J Med. 2006;99:15-22.
6. Dakeishi M, Shioya T, Wada Y, Shindo T, Otaka K, Manabe M, et al. Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan. Hum Mutat. 2002;19:140-8.
7. Guttmacher AE, Marchuk DA, White RI Jr. Hereditary hemorrhagic telangiectasia. N Engl J Med. 1995;333:918-24.
8. Shovlin CL, Hughes JMB, Tuddenham EGD, Temperley I, Perembelon YFN, Scott J, et al. A gene for hereditary hemorrhagic telangiectasia maps to chromosome 9q33. Nat Genet. 1994;6:205-9.
9. McDonald MT, Papenberg KA, Ghosh S, Glatfelter A, Biesecker BB, Helmbold EA, et al. A disease locus for hereditary haemorrhagic telangiectasia maps to chromosome 9q33-q34. Nat Genet. 1994;6:197-204.
10. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 1994;8:345-51.
11. Gallione CJ, Scheessele EA, Reinhardt D, Duits AJ, Berg JN, Westermann CJJ, et al. Two common endoglin mutations in families with hereditary hemorrhagic telangiectasia in the Netherlands Antilles: Evidence for a founder effect. Hum Genet. 2000;107:40-4.
12. Vincent P, Plauchu H, Hazan J, Faure S, Weissenbach J, Godet J. A third locus for hereditary haemorrhagic telangiectasia maps to chromosome 12q. Hum Mol Genet. 1995;4:945-9.
13. Johnson DW, Berg JN, Gallione CJ, McAllister KA, Warner JP, Helmbold EA, et al. A second locus for hereditary hemorrhagic telangiectasia maps to chromosome 12. PCR Methods Appl. 1995;5:21-8.
14. Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet. 1996;13:189-95.
15. McAllister KA, Lennon F, Bowles-Biesecker B, McKinnon WC, Helmbold EA, Markel DS, et al. Genetic heterogeneity in hereditary haemorrhagic telangiectasia: Possible correlation with clinical phenotype. J Med Genet. 1994;31:927-32.
16. Heutink P, Haitjema T, Breedveld GJ, Janssen B, Sandkuijl LA, Botenkoe CJM, et al. Linkage of hereditary haemorrhagic telangiectasia to chromosome 9q34 and evidence for locus heterogeneity. J Med Genet. 1994;31:933-6.
17. Berg JN, Guttmacher AE, Marchuk DA, Porteous ME. Clinical heterogeneity in hereditary haemorrhagic telangiectasia: Are pulmonary arteriovenous malformations more common in families linked to endoglin? J Med Genet. 1996;33:256-7.
18. Haitjema T, Westermann CJ, Overtoom TT, Timmer R, Disch F, Mauser H, et al. Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease): New insights in pathogenesis, complications, and treatment. Arch Intern Med. 1996;156:714-19.
19. Gallione CJ, Repetto GM, Legius E, Rustgi AK, Schelley SL, Tejpar S, et al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet. 2004;363:852-9.
20. Urushihara M, Furukawa S, Ota A, Iwai A, Matsumura K, Hamada Y. Hemorrhagic telangiectasia with thrombocytopenia in a newborn infant. Pediatr Int. 2000;42:693-5.
21. Jacobson BS. Hereditary hemorrhagic telangiectasia. A model for blood vessel growth and enlargement. Am J Pathol. 2000;156:737-42.
22. Harries PG, Brockbank MJ, Shakespeare PG, Carruth JAS. Treatment of hereditary haemorrhagic telangiectasia by the pulsed dye laser. J Laryngol Otol. 1997;111:1038-41.
23. Poblete-Gutiérrez P, Rübben A, Merk HF, Frank J. Unilateral facial telangiectases suggest type 1 segmental manifestation of Osler-Rendu-Weber syndrome in an 11-year-old boy. Eur J Dermatol. 2003;13:537-9.
24. Ben-Bassat M, Kaplan MB, Levy R. Treatment of hereditary hemorrhagic telangiectasias of the nasal mucosa with the carbon dioxide laser. Br J Plast Surg. 1978;31:157-8.
25. Parkin JL, Dixon JA. Laser photocoagulation in hereditary hemorrhagic telangiectasias. Otolaryngol Head Neck Surg. 1981;89:204-8.
26. Shapsay SM, Oliver P. Treatment of hereditary hemorrhagic telangiectasias by Nd-YAG laser photocoagulation. Laryngoscope. 1984;94:1554-6.
27. Werner JA, Lippert BM, Geisthoff UW, Rudert H. [Nd:YAG laser therapy of recurrent epistaxis in hereditary hemorrhagic telangiectasias.] Laryngorhinootologie. 1997;76:495-501.
28. Apfelberg DB, Maser MR, Lash H, Flores J. Expanded role of the argon laser in plastic surgery. J Dermatol Surg Oncol. 1983;9:145-51.
29. Haye R, Austad J. Hereditary hemorrhagic teleangiectasia - argon laser. Rhinology. 1991;29:5-9.
30. Vickery CL, Kuhn FA. Using the KTP/532 laser to control epistaxis in patients with hereditary hemorrhagic telangiectasia. South Med J. 1996;89:78-80.
31. Ducic Y, Brownrigg P, Laughlin S. Treatment of haemorrhagic telangiectasia with the flashlamp-pulsed dye laser. J Otolaryngol. 1995;24:299-302.
32. Harries PG, Brockbank MJ, Shakespeare PG, Carruth JA. Treatment of hereditary haemorrhagic telangiectasia by the pulsed dye laser. J Laryngol Otol. 1997;111:1038-41.
33. Ramirez B, Morais D, Condado MA, Marcos M, Martín G, Poncela M. [A new sclerosant for the treatment of Rendu-Osler-Weber disease.] Acta Otorrinolaringol Esp. 2000;51:36-9.
34. Morais D, Ramírez B, Santos J. [Local sclerosant treatment with etoxiesclerol in ENT pathologies: Rendu-Osler-Weber disease, granulomas, angiomas.] Acta Otorrinolaringol Esp. 2002;53:658-61.
35. Raulin C, Weiss RA, Schonermark MP. Treatment of essential telangiectasias with an intense pulsed light source (PhotoDerm VL). Dermatol Surg. 1997;23:941-5.
36. Raulin C, Greve B, Grema H. IPL technology: A review. Lasers Surg Med. 2003;32:78-87.
37. Ruiz-Esparza J, Goldman MP, Fitzpatrick RE, Lowe NJ, Behr KL. Flash lamp-pumped dye laser treatment of telangiectasia. J Dermatol Surg Oncol. 1993;19:1000-3.
38. Gambichler T, Avermaete A, Wilmert M, Altmeyer P, Hoffmann K. Generalized essential telangiectasia successfully treated with high-energy, long-pulse, frequency-doubled Nd:YAG laser. Dermatol Surg. 2001;27:355-7.
39. Purcell E, Condon C. Intense pulsed light therapy in the management of hereditary benign telangiectasia. Br J Plast Surg. 2004;57:453-5.
40. Grenz H, Peschen M, Wiek K, Schopf E, Vanscheidt W. Hereditary benign telangiectasia: A rare form of primary telangiectasia with successful treatment with flash-lamp-pumped pulsed dye laser. Vasa. 1998;27:192-5.
41. Clementoni MT, Gilardino P, Muti GF, Signorini M, Pistorale A, Morselli PG, et al. Facial teleangectasias: Our experience in treatment with IPL. Lasers Surg Med. 2005;37:9-13.
42. Bjerring P, Christiansen K, Troilius A. Intense pulsed light source for treatment of facial telangiectasias. J Cosmet Laser Ther. 2001;3:169-73.
43. Angermeier MC. Treatment of facial vascular lesions with intense pulsed light. J Cutan Laser Ther. 1999;1:95-100.
44. Schroeter CA, Neumann HA. An intense light source. The photoderm VL-flashlamp as a new treatment possibility for vascular skin lesions. Dermatol Surg. 1998;24:743-8.
45. Smit JM, Bauland CG, Wijnberg DS, Spauwen PH. Pulsed dye laser treatment, a review of indications and outcome based on published trials. Br J Plast Surg. 2005;58:981-7.
46. Goldman MP. Optimal management of facial telangiectasia. Am J Clin Dermatol. 2004;5:423-34.
47. Clark C, Cameron H, Moseley H, Ferguson J, Ibbotson SH. Treatment of superficial cutaneous vascular lesions: Experience with the KTP 532 nm laser. Lasers Med Sci. 2004;19:1-5.
48. Alam M, Dover JS, Arndt KA. Treatment of facial telangiectasia with variable-pulse high-fluence pulsed-dye laser: Comparison of efficacy with fluences immediately above and below the purpura threshold. Dermatol Surg. 2003;29:681-4.
49. Adrian RM, Tanghetti EA. Long pulse 532-nm laser treatment of facial telangiectasia. Dermatol Surg. 1998;24:71-4.
50. McCoy SE. Copper bromide laser treatment of facial telangiectasia: Results of patients treated over five years. Lasers Surg Med. 1997;21:329-40.
51. McCoy S, Hanna M, Anderson P, McLennan G, Repacholi M. An evaluation of the copper-bromide laser for treating telangiectasia. Dermatol Surg. 1996;22:551-7.
52. Levine VJ, Geronemus RG. Adverse effects associated with the 577- and 585-nanometer pulsed dye laser in the treatment of cutaneous vascular lesions: a study of 500 patients. J Am Acad Dermatol. 1995;32:613-17.
53. Garden JM, Bakus AD. Clinical efficacy of the pulsed dye laser in the treatment of vascular lesions. J Dermatol Surg Oncol. 1993;19:321-6.
54. Neumann RA, Leonhartsberger H, Bohler-Sommeregger K, Knobler R, Kokoschka EM, Honigsmann H. Results and tissue healing after copper-vapour laser (at 578 nm) treatment of port wine stains and facial telangiectasias. Br J Dermatol. 1993;128:306-12.
55. Rosenfeld H, Sherman R. Treatment of cutaneous and deep vascular lesions with the Nd:YAG laser. Lasers Surg Med. 1986;6:20-3, 50-1.
56. Craig RD, Purser JM, Lessells AM, Hufton AP. Argon laser therapy for cutaneous lesions. Br J Plast Surg. 1985;38:148-55.
57. Apfelberg DB, Maser MR, Lash H, Rivers J. The argon laser for cutaneous lesions. JAMA. 1981;245:2073-5.
58. Apfelberg DB, Maser MR, Lash H. Extended clinical use of the argon laser for cutaneous lesions. Arch Dermatol. 1979;115:719-21.
59. Apfelberg DB, Maser MR, Lash H. Argon laser management of cutaneous vascular deformities. A preliminary report. West J Med. 1976;124:99-101.
60. Ellis DL. Treatment of telangiectasia macularis eruptiva perstans with the 585-nm flashlamp-pumped dye laser. Dermatol Surg. 1996;22:33-7.
61. Dave RU, Mahaffey PJ, Monk BE. Cutaneous lesions in hereditary haemorrhagic telangiectasia: Successful treatment with the tunable dye laser. J Cutan Laser Ther. 2000;2:191-3.
62. Lyons GD, Owens RE, Mouney DF. Argon laser destruction of cutaneous telangiectatic lesions. Laryngoscope. 1981;91:1322-5.